Sepsis-associated encephalopathy represents a multifaceted brain dysfunction triggered by systemic infection and the ensuing uncontrolled immune response. It manifests clinically as an acute cognitive decline, delirium, and long-term cognitive impairment, substantially increasing mortality rates. Despite extensive research, effective treatments have remained elusive, largely due to an incomplete understanding of the cellular and molecular mechanisms underpinning neuroinflammation in this context. The new focus on the GAS6/AXL axis signifies a paradigm shift, highlighting a specific signaling cascade that encourages the clearance of apoptotic cells by microglia, thereby mitigating the inflammatory milieu in the brain during sepsis.

Microglia, the resident immune cells of the central nervous system, are pivotal mediators of both neuroinflammation and tissue repair. These highly plastic cells can assume distinct functional phenotypes, broadly categorized into pro-inflammatory M1 and anti-inflammatory M2 states. The balance between these phenotypes greatly influences the neurological outcome following systemic infections. The study in question elucidates how GAS6, a vitamin K-dependent protein known to bind and activate the receptor tyrosine kinase AXL, orchestrates a shift toward the M2 phenotype in microglia. This shift favors the engulfment and removal of apoptotic debris — a process termed efferocytosis — which is essential for resolving inflammation and promoting tissue homeostasis.

The interaction between GAS6 and AXL triggers an intracellular signaling cascade that enhances microglial mobility and phagocytic efficacy. By promoting efferocytosis, GAS6/AXL signaling effectively limits the release of pro-inflammatory cytokines and neurotoxic mediators that exacerbate neuronal injury. The study provides intricate molecular data demonstrating how this signaling influences downstream effectors, such as PI3K/Akt and MAPK pathways, which further potentiate anti-inflammatory responses and microglial survival. The net effect is a reduction in neuroinflammatory damage and a protective microenvironment conducive to neuronal recovery.

These insights are particularly significant considering that the accumulation of apoptotic cells and cellular debris in the brain during sepsis greatly impairs neural function and perpetuates inflammation. Efficient clearance through efferocytosis not only prevents secondary necrosis but also triggers an immunoregulatory phenotype in microglia, characterized by the release of growth factors like TGF-β and IL-10. This contributes to the suppression of ongoing inflammatory responses and fosters repair processes. The elucidation of GAS6/AXL-mediated enhancement of these mechanisms thus identifies a finely tuned neuroprotective network potentially exploitable for therapeutic intervention.

In exploring the translational potential of these findings, the authors have demonstrated that pharmacological activation of AXL signaling significantly improves neurological outcomes in experimental models of SAE. Notably, mice subjected to endotoxin-induced sepsis exhibited decreased cognitive deficits and improved survival rates following treatment that boosted GAS6 levels or directly stimulated AXL receptors on microglia. This suggests a viable strategy to modulate innate immunity within the CNS without broadly suppressing systemic immune function — a critical consideration given the susceptibility of septic patients to secondary infections.

Furthermore, the study presents a comprehensive temporal profile of microglial phenotype changes during the progression of sepsis-induced brain injury. Initially, the inflammatory cascade is dominated by M1 activation and pro-inflammatory cytokine storms, but GAS6/AXL signaling mediates a subsequent switch to a reparative M2 state. This dynamic transition is vital for timely resolution of neurological inflammation and highlights a therapeutic window during which intervention could be particularly efficacious. Understanding this temporal relationship aids in designing therapies that maximize benefits while minimizing unintended immunosuppression.

Beyond the context of sepsis, the implications of regulating GAS6/AXL-mediated efferocytosis extend to other neurodegenerative and neuroinflammatory disorders, such as Alzheimer’s disease, multiple sclerosis, and stroke. Microglial dysfunction and impaired clearance of cellular debris are common pathological features across these conditions. By harnessing the natural mechanisms of immune quiescence and repair elucidated in this research, broader neurotherapeutic strategies could emerge with the potential to slow disease progression and improve patient quality of life.

The technical rigor of the study is underpinned by state-of-the-art approaches, including sophisticated in vivo imaging to track microglial activity, gene knockout models to ascertain pathway specificity, and advanced flow cytometry to delineate microglial phenotypes. Proteomic and transcriptomic analyses further elucidate the molecular undercurrents activated by GAS6/AXL signaling, offering a detailed blueprint of the signaling landscape. These multifaceted methodologies corroborate the conclusion that augmenting this pathway can recalibrate microglial function toward neuroprotection.

Crucially, the study also addresses potential challenges in targeting GAS6/AXL therapeutically. Because AXL signaling has been implicated in oncogenesis in other tissues, the systemic modulation of this pathway necessitates careful balancing to avoid unwanted side effects. The authors propose localized delivery methods and selective activation strategies to mitigate these risks. Such precision medicine approaches resonate with the increasing trend toward tailored treatments that optimize efficacy while minimizing harm.

The correction and clarification provided in the referenced article reinforce the robustness of these findings and ensure the scientific community can build on this knowledge with confidence. By resolving discrepancies and updating key data points regarding the GAS6/AXL pathway’s role, the researchers demonstrate commendable commitment to transparency and accuracy, which will facilitate accelerated clinical translation.

In sum, this pioneering work elucidates a vital neuroimmune mechanism by which GAS6/AXL signaling orchestrates M2 microglia efferocytosis, offering a lifeline against the relentless neuroinflammation of sepsis-associated encephalopathy. Its implications reverberate beyond the immediate context of sepsis, carving a path toward novel immunomodulatory therapies for a spectrum of CNS disorders. As preclinical findings advance towards clinical application, patients suffering from devastating neurological sequelae may soon benefit from treatments grounded in the elegant biology of microglial efferocytosis.

As the global burden of sepsis continues to climb, with millions affected annually, the urgency for innovative treatments has never been more critical. The discovery detailed herein not only deepens foundational scientific understanding but also galvanizes hope for interventions that can transform clinical outcomes. By leveraging the brain’s innate capacity for repair through GAS6/AXL-driven microglial activation, a new frontier in neuroimmune therapy stands poised for exploration and exploitation.

Future research will undoubtedly focus on optimizing pharmacological agents that selectively harness GAS6/AXL signaling, validating their efficacy and safety in human populations. Concurrently, elucidating potential interactions with other neuroimmune pathways and determining long-term effects will be vital to fully harness the therapeutic scope unveiled by these innovative findings. The integration of such approaches into holistic management protocols for sepsis and related CNS inflammatory conditions may well define the next era of neurocritical care.

The intricate dance of immune modulation and neuronal preservation revealed in this study exemplifies the power of targeted molecular research to address complex pathologies. The GAS6/AXL axis emerges as a central conductor directing microglial orchestration of neuroinflammation, transforming our conceptual and therapeutic landscape. This represents a beacon of hope amid the clinical challenges of sepsis-associated encephalopathy, propelling the field towards a future where neuroinflammation is not an intractable foe, but a manageable and treatable phenomenon.

Subject of Research: Neuroinflammation and microglial efferocytosis mechanisms in sepsis-associated encephalopathy, focusing on GAS6/AXL signaling pathways.

Article Title: Correction: GAS6/AXL signaling promotes M2 microglia efferocytosis to alleviate neuroinflammation in sepsis-associated encephalopathy.

Article References:
Tang, Y., Hu, H., Xie, Q. et al. Correction: GAS6/AXL signaling promotes M2 microglia efferocytosis to alleviate neuroinflammation in sepsis-associated encephalopathy. Cell Death Discov. 11, 531 (2025). https://doi.org/10.1038/s41420-025-02706-3

Image Credits: AI Generated

Sepsis-associated encephalopathy represents a diffuse cerebral dysfunction triggered by systemic infection and inflammation, characterized by delirium, cognitive deficits, and long-term neurological impairment. Central to this pathology is an overactive immune response that compromises the delicate homeostasis of the central nervous system (CNS). Microglia, the brain-resident macrophages, orchestrate the neuroimmune response, modulating inflammation, clearing cellular debris, and maintaining neural circuitry integrity. Among microglial phenotypes, the alternatively activated M2 type is associated with anti-inflammatory and reparative functions. Understanding how these microglia coordinate efferocytosis—the process of engulfing and removing apoptotic cells—has remained a critical gap until now.

The researchers focused on the GAS6 (growth arrest-specific 6) protein and its receptor, AXL, a receptor tyrosine kinase belonging to the TAM family, known to regulate immune homeostasis and cell clearance. Prior studies had hinted at the GAS6/AXL axis’s involvement in diverse inflammatory settings, but its precise role within the CNS microenvironment during sepsis remained elusive. Through a combination of in vivo and in vitro experiments utilizing murine models of sepsis and primary microglial cultures, the study delineated how GAS6 binding to AXL on M2 microglia dramatically enhanced their efferocytic capacity.

Mechanistically, activation of AXL triggered downstream signaling cascades, including the PI3K/Akt and ERK pathways, which are vital for cytoskeletal remodeling and phagosome formation. These intracellular events facilitated the efficient recognition, engulfment, and degradation of apoptotic neurons and cellular debris resulting from sepsis-induced brain injury. Notably, inhibiting the GAS6/AXL axis suppressed efferocytosis, exacerbating neuroinflammation and neurodegeneration, thereby underscoring its protective role. This phenomenon was accompanied by a reduction in pro-inflammatory cytokines such as IL-1β and TNF-α and an increase in anti-inflammatory mediators like IL-10, indicating a balanced immune milieu fostered by GAS6/AXL signaling.

One of the notable strengths of this work lies in its detailed dissection of microglial polarization dynamics. By leveraging flow cytometry, immunohistochemistry, and gene expression analyses, the investigators demonstrated that the GAS6/AXL pathway preferentially enhanced M2 microglial phenotypes while dampening pro-inflammatory M1 characteristics. This shift was crucial in containing the deleterious effects of systemic inflammation on brain tissue. Furthermore, the study revealed temporal nuances where GAS6/AXL activation was most pronounced during the acute phases of sepsis, highlighting a window of opportunity for therapeutic intervention.

In addition to advancing molecular understanding, the researchers explored translational potential by administering recombinant GAS6 protein to septic animal models. Treatment not only augmented microglial efferocytosis but also significantly improved neurological outcomes, measured through behavioral assays assessing motor coordination and cognitive functions. These promising results set a precedent for future clinical trials aimed at harnessing GAS6/AXL signaling to treat SAE patients.

Sepsis-associated encephalopathy remains poorly understood, partly due to the complexity of immune-brain interactions and the heterogeneity of patient presentations. This study’s comprehensive approach combining molecular biology, neuroimmunology, and in vivo modeling offers a robust framework to unravel these complexities. The identification of GAS6/AXL as a key regulator of neuroprotective microglial functions presents a paradigm shift, moving beyond systemic infection control toward targeted modulation of CNS immunity.

The implications of these findings extend beyond sepsis, potentially influencing therapeutic strategies for other neuroinflammatory disorders such as Alzheimer’s disease, multiple sclerosis, and traumatic brain injury, where aberrant microglial activation plays a detrimental role. By restoring efferocytosis and fostering tissue repair, manipulation of the GAS6/AXL pathway could represent a universal mechanism to modulate CNS inflammation safely.

Importantly, the study carefully considered the safety profile of manipulating GAS6/AXL signaling. Given AXL’s involvement in cancer progression and immune evasion in tumors, the authors emphasize the need for precise targeting and timing in potential therapies to avoid unintended oncogenic effects. Nonetheless, the CNS-specific delivery and localized activation strategies could mitigate such risks, making GAS6/AXL modulation a viable therapeutic target with minimal systemic adverse effects.

This research also paves the way for biomarker development. Elevated levels of GAS6 or soluble AXL in cerebrospinal fluid or blood could serve as diagnostic indicators for the severity of SAE or treatment efficacy. Such biomarkers would be invaluable in the clinical setting for patient stratification, prognosis, and monitoring therapeutic responses in real time.

In conclusion, the elucidation of the GAS6/AXL signaling axis as a promoter of M2 microglial efferocytosis marks a significant advance in understanding neuroimmune crosstalk during sepsis-associated encephalopathy. By harnessing this pathway, future therapies may significantly reduce the burden of cognitive impairment and mortality associated with sepsis-related brain dysfunction. Continued research into the molecular intricacies and translational applications of this pathway will undoubtedly reshape approaches to managing sepsis and other devastating neuroinflammatory conditions.

As the scientific community strives to combat the global burden of sepsis and its neurological complications, discoveries such as these offer hope for novel, mechanism-based interventions that enhance the body’s innate ability to heal the brain. The GAS6/AXL axis stands out as a beacon in this landscape, illuminating new frontiers in neuroimmunology and clinical neuroscience.

Subject of Research: GAS6/AXL signaling and its role in promoting M2 microglial efferocytosis to alleviate neuroinflammation in sepsis-associated encephalopathy.

Article Title: GAS6/AXL signaling promotes M2 microglia efferocytosis to alleviate neuroinflammation in sepsis-associated encephalopathy.

Article References: Tang, Y., Hu, H., Xie, Q. et al. GAS6/AXL signaling promotes M2 microglia efferocytosis to alleviate neuroinflammation in sepsis-associated encephalopathy. Cell Death Discov. 11, 268 (2025). https://doi.org/10.1038/s41420-025-02507-8

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02507-8